Thermo Fisher Scientific TMO Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Consolidated revenues by Business | |||||
| Analytical Instruments | $7.55B+1.2% | $7.46B+2.8% | $7.26B+9.6% | $6.62B+9.1% | |
| Laboratory Products and Biopharma Services | $23.98B— | —— | $23.04B— | —— | |
| Life Sciences Solutions | $10.37B+7.7% | $9.63B-3.5% | $9.98B-26.3% | $13.53B-13.4% | |
| Specialty Diagnostics | $4.68B+3.6% | $4.51B+2.4% | $4.41B-7.5% | $4.76B-15.8% | |
| Cost of revenues by Business | |||||
| Analytical Instruments | $3.85B— | —— | $3.47B— | —— | |
| Laboratory Products and Biopharma Services | $18.61B— | —— | $17.98B— | —— | |
| Life Sciences Solutions | $3.93B— | —— | $4.08B— | —— | |
| Specialty Diagnostics | $2.72B— | —— | $2.58B— | —— | |
| Operating Income (Loss) by Business | |||||
| Analytical Instruments | $1.74B-11.2% | $1.96B+2.5% | $1.91B+26.6% | $1.51B+25.9% | |
| Laboratory Products and Biopharma Services | $3.35B— | —— | $3.36B— | —— | |
| Life Sciences Solutions | $3.77B+7.6% | $3.5B+2.4% | $3.42B-38.7% | $5.58B-28.6% | |
| Specialty Diagnostics | $1.26B+8.4% | $1.16B+3.1% | $1.12B+9.8% | $1.02B-20.0% | |
| Other segment items by Business | |||||
| Analytical Instruments | $151M— | —— | $116M— | —— | |
| Laboratory Products and Biopharma Services | -$422M— | —— | -$638M— | —— | |
| Life Sciences Solutions | $213M— | —— | $155M— | —— | |
| Specialty Diagnostics | -$183M— | —— | -$174M— | —— | |
| Selling, general and administrative expenses by Business | |||||
| Analytical Instruments | $1.24B— | —— | $1.24B— | —— | |
| Laboratory Products and Biopharma Services | $2.39B— | —— | $2.28B— | —— | |
| Life Sciences Solutions | $1.91B— | —— | $1.77B— | —— | |
| Specialty Diagnostics | $708M— | —— | $716M— | —— | |
| Currency translation by Business | |||||
| Analytical Instruments | $184M+300% | -$92M-267% | $55M+154% | -$102M-10.9% | |
| Laboratory Products and Biopharma Services | $444M+464% | -$122M— | —— | —— | |
| Life Sciences Solutions | $473M+504% | -$117M-2,440% | $5M+183% | -$6M+14.3% | |
| Specialty Diagnostics | $292M+310% | -$139M-253% | $91M+149% | -$186M-84.2% | |
| Research and development expenses by Business | |||||
| Analytical Instruments | $573M— | —— | $528M— | —— | |
| Laboratory Products and Biopharma Services | $56M— | —— | $68M— | —— | |
| Life Sciences Solutions | $553M— | —— | $558M— | —— | |
| Specialty Diagnostics | $178M— | —— | $156M— | —— | |
| Acquisitions by Business | |||||
| Analytical Instruments | $0— | $0-100% | $31M+29.2% | $24M-57.1% | |
| Laboratory Products and Biopharma Services | $15M— | $0— | —— | —— | |
| Life Sciences Solutions | $2.1B-8.7% | $2.3B— | $0— | $0-100% | |
| Specialty Diagnostics | $0— | $0-100% | $1.74B— | $0-100% | |
| Purchases of property, plant and equipment by Business | |||||
| Analytical Instruments | $124M— | —— | $87M-37.9% | $140M+77.2% | |
| Laboratory Products and Biopharma Services | $1.01B— | —— | $1.01B— | —— | |
| Life Sciences Solutions | $152M— | —— | $178M-63.7% | $490M-39.5% | |
| Specialty Diagnostics | $128M— | —— | $121M+8.0% | $112M-32.9% | |
| Depreciation of property, plant and equipment by Business | |||||
| Analytical Instruments | $104M— | —— | $93M+12.0% | $83M0.0% | |
| Laboratory Products and Biopharma Services | $604M— | —— | $669M— | —— | |
| Life Sciences Solutions | $251M— | —— | $220M+2.8% | $214M+8.6% | |
| Specialty Diagnostics | $91M— | —— | $86M+14.7% | $75M-41.4% | |
| Consolidated revenues by Product | |||||
| Consumables | $18.66B+6.1% | $17.59B-0.1% | $17.6B-14.7% | $20.62B-8.8% | |
| Instruments | $7.3B-1.9% | $7.45B-2.6% | $7.65B-3.5% | $7.92B+2.2% | |
| Service revenues | $18.59B+4.2% | $17.85B+1.3% | $17.61B+7.6% | $16.37B+84.9% | |
| Consolidated revenues by Geography | |||||
| Asia-Pacific | $8.1B+1.8% | $7.96B+1.1% | $7.87B-3.0% | $8.12B+12.4% | |
| Europe | $11.83B+8.9% | $10.86B+1.1% | $10.74B-0.2% | $10.76B-3.3% | |
| North America | $23.03B+2.4% | $22.5B-1.1% | $22.76B-7.4% | $24.59B+25.1% | |
| Other regions | $1.6B+2.3% | $1.56B+5.5% | $1.48B+2.4% | $1.44B+20.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Thermo Fisher Scientific break its business down?
- Thermo Fisher Scientific (TMO) reports consolidated revenues by business across 4 parts — Analytical Instruments, Laboratory Products and Biopharma Services, Life Sciences Solutions and Specialty Diagnostics. Each is extracted from the segment footnotes and tracked over time.
- Where does Thermo Fisher Scientific's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Thermo Fisher Scientific's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
